Literature DB >> 25352470

Periosteal microcirculatory reactions in a zoledronate-induced osteonecrosis model of the jaw in rats.

Ágnes Janovszky1, Andrea Szabó, Renáta Varga, Dénes Garab, Mihály Boros, Csilla Mester, Nikolett Beretka, Tamás Zombori, Hans-Peter Wiesmann, Ricardo Bernhardt, Imre Ocsovszki, Péter Balázs, József Piffkó.   

Abstract

OBJECTIVES: Nitrogen-containing bisphosphonates induce osteonecrosis mostly in the jaw and less frequently in other bones. Because of the crucial role of periosteal perfusion in bone repair, we investigated zoledronate-induced microcirculatory reactions in the mandibular periosteum in comparison with those in the tibia in a clinically relevant model of bisphosphonate-induced medication-related osteonecrosis of the jaw (MRONJ).
MATERIALS AND METHODS: Sprague-Dawley rats were treated with zoledronate (ZOL; 80 i.v. μg/kg/week over 8 weeks) or saline vehicle. The first two right mandibular molar teeth were extracted after 3 weeks. Various systemic and local (periosteal) microcirculatory inflammatory parameters were examined by intravital videomicroscopy after 9 weeks.
RESULTS: Gingival healing disorders (∼100%) and MRONJ developed in 70% of ZOL-treated cases but not after saline (shown by micro-CT). ZOL induced significantly higher degrees of periosteal leukocyte rolling and adhesion in the mandibular postcapillary venules (at both extraction and intact sites) than at the tibia. Leukocyte NADPH-oxidase activity was reduced; leukocyte CD11b and plasma TNF-alpha levels were unchanged.
CONCLUSION: Chronic ZOL treatment causes a distinct microcirculatory inflammatory reaction in the mandibular periosteum but not in the tibia. The local reaction in the absence of augmented systemic leukocyte inflammatory activity suggests that topically different, endothelium-specific changes may play a critical role in the pathogenesis of MRONJ. CLINICAL RELEVANCE: This model permits for the first time to explore the microvascular processes in the mandibular periosteum after chronic ZOL treatment. This approach may contribute to a better understanding of the pathomechanism and the development of strategies to counteract bisphosphonate-induced side effects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25352470     DOI: 10.1007/s00784-014-1347-6

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  39 in total

Review 1.  Bisphosphonates: mechanisms of action.

Authors:  G A Rodan; H A Fleisch
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

2.  Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice.

Authors:  Yasuyoshi Kobayashi; Toru Hiraga; Akimi Ueda; Liyang Wang; Michiyo Matsumoto-Nakano; Kenji Hata; Hirofumi Yatani; Toshiyuki Yoneda
Journal:  J Bone Miner Metab       Date:  2009-10-31       Impact factor: 2.626

3.  Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate.

Authors:  D Wen; L Qing; G Harrison; E Golub; S O Akintoye
Journal:  Oral Dis       Date:  2010-12-02       Impact factor: 3.511

4.  Zoledronate and pamidronate depress neutrophil functions and survival in mice.

Authors:  J W P Kuiper; C Forster; C Sun; S Peel; M Glogauer
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Effects of pamidronate on human alveolar osteoblasts in vitro.

Authors:  Darja Marolt; Matthew Cozin; Gordana Vunjak-Novakovic; Serge Cremers; Regina Landesberg
Journal:  J Oral Maxillofac Surg       Date:  2012-05       Impact factor: 1.895

6.  The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells.

Authors:  Y Açil; B Möller; P Niehoff; K Rachko; V Gassling; J Wiltfang; M J K Simon
Journal:  J Craniomaxillofac Surg       Date:  2011-11-13       Impact factor: 2.078

7.  The influence of bisphosphonates on human osteoblast migration and integrin aVb3/tenascin C gene expression in vitro.

Authors:  Felix P Koch; Annette Wunsch; Christina Merkel; Thomas Ziebart; Andreas Pabst; Sareh Said Yekta; Marco Blessmann; Ralf Smeets
Journal:  Head Face Med       Date:  2011-02-07       Impact factor: 2.151

8.  Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis.

Authors:  Mark A Scheper; Ashraf Badros; Risa Chaisuparat; Kevin J Cullen; Timothy F Meiller
Journal:  Br J Haematol       Date:  2008-11-20       Impact factor: 6.998

9.  In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes.

Authors:  Nadine Hagelauer; Andreas Max Pabst; Thomas Ziebart; Holger Ulbrich; Christian Walter
Journal:  Clin Oral Investig       Date:  2014-03-26       Impact factor: 3.573

10.  Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw.

Authors:  X Wei; S Pushalkar; C Estilo; C Wong; A Farooki; M Fornier; G Bohle; J Huryn; Y Li; S Doty; D Saxena
Journal:  Oral Dis       Date:  2012-03-23       Impact factor: 3.511

View more
  5 in total

Review 1.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

Review 2.  Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials.

Authors:  Henrik Holtmann; Julian Lommen; Norbert R Kübler; Christoph Sproll; Majeed Rana; Patrick Karschuck; Rita Depprich
Journal:  J Int Med Res       Date:  2018-08-09       Impact factor: 1.671

Review 3.  Medication-Related Osteonecrosis of the Jaw (MRONJ): Are Antiresorptive Drugs the Main Culprits or Only Accomplices? The Triggering Role of Vitamin D Deficiency.

Authors:  Luca Dalle Carbonare; Monica Mottes; Maria Teresa Valenti
Journal:  Nutrients       Date:  2021-02-08       Impact factor: 5.717

Review 4.  Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  Ran Yan; Ruixue Jiang; Longwei Hu; Yuwei Deng; Jin Wen; Xinquan Jiang
Journal:  Int J Oral Sci       Date:  2022-08-10       Impact factor: 24.897

5.  Beta tricalcium phosphate, either alone or in combination with antimicrobial photodynamic therapy or doxycycline, prevents medication-related osteonecrosis of the jaw.

Authors:  Henrique Hadad; Laís Kawamata de Jesus; Ana Flávia Piquera Santos; Henrique Rinaldi Matheus; Letícia Gabriella de Souza Rodrigues; Pier Paolo Poli; Elcio Marcantonio Junior; Fernando Pozzi Semeghini Guastaldi; Carlo Maiorana; Juliano Milanezi de Almeida; Roberta Okamoto; Francisley Ávila Souza
Journal:  Sci Rep       Date:  2022-10-03       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.